MR. GABRIEL S KHODR, MD
Medical Practice in San Antonio, TX

7834141, Nov 16, 2010

Mar 31, 2000

09/540685

Gabriel S. Khodr - San Antonio TX, US

C07K 7/00, C07K 7/23, C07K 14/575

530313, 530328, 530332, 530333, 530335, 514 2, 514 15

Specially designed non-mammalian GnRH analogs resistant to degradation by the tumor tissue enzymes, post-proline peptidases as well as endopeptidases, are disclosed. The GnRH analogs are further defined as analogs of chicken II GnRH, salmon GnRH, or herring GnRH, but can include any non-mammalian GnRH analog with similar amino acid structure. These non-mammalian analogs incorporate D-arginine, D-leucine, D-tBu-Serine or D-Trp or other similar amino acids at position 6 and ethylamide or aza-Gly-amide or similar amides at position 10. These analogs demonstrate preferential binding to tumor cell GnRH receptors that is greater relative to the binding of the mammalian analogs to the tumor cell GnRH receptor. These non-mammalian GnRH analogs may be used in pharmaceutical preparations, and it specifically in various treatments as an anti-tumor, anti-proliferation, anti-metastatic and/or an apoptotic agent. The non-mammalian GnRH analogs are also provided in pharmaceutical preparations that may be used clinically for tumor regression when used in very low doses and administered in pulsatile fashion.

2004009, May 20, 2004

Sep 3, 2003

10/654192

Gabriel Khodr - San Antonio TX, US

C07K014/60

514/008000, 530/397000

Specially designed non-mammalian GnRH analogs resistant to degradation by the tumor tissue enzymes, post-proline peptidases as well as endopeptidases, are disclosed. The GnRH analogs are further defined as analogs of chicken II GnRH, salmon GnRH, or herring GnRH, but can include any non-mammalian GnRH analog with similar amino acid structure. These non-mammalian analogs incorporate D-arginine, D-leucine, D-tBu-Serine or D-Trp or other similar amino acids at position 6 and ethylamide or aza-Gly-amide or similar amides at position 10. These analogs demonstrate preferential binding to tumor cell GnRH receptors that is greater relative to the binding of the mammalian analogs to the tumor cell GnRH receptor. These non-mammalian GnRH analogs may be used in pharmaceutical preparations, and specifically in various treatments as an anti-tumor, anti-proliferation, anti-metastatic and/or an apoptotic agent. The non-mammalian GnRH analogs are also provided in pharmaceutical preparations that may be used clinically for tumor regression when used in very low doses and administered in pulsatile fashion.

4945055, Jul 31, 1990

May 15, 1986

6/863310

Thomas J. Kuehl - San Antonio TX
M. J. K. Harper - San Antonio TX
Gabriel S. Khodr - San Antonio TX

Board of Regents, University of Texas System - Austin TX

C12N 964

435226

A substantially purified human chorionic gonadotropin releasing factor (hCG-RF) which is a glycoprotein with a molecular weight between about 50,000 and about 70,000. This hCG-RF is capable of stimulating release of human chorionic gonadotropin as well as prostaglandins, particularly from human term placental cultures. This hCG-RF is capable of degrading GnRH and is isolatable from human placenta, preferably term placenta. Such hCG-RF may be used to affect a state of pregnancy, particularly mammalian pregnancy. This effect upon pregnancy may comprise the induction of a normal labor.